Tremelimumab-actl是一种单克隆抗体,它结合CTLA-4并阻断与其配体CD80和CD86的相互作用,释放CTLA-4介导的T细胞活化抑制。在协同小鼠肿瘤模型中,阻断CTLA-4活性导致肿瘤生长减少和肿瘤中T细胞增殖增加。 曲美木单抗联合度伐利尤单抗(Durvalumab)的疗效在HIMALAYA(NCT03298451)研究中进行了评估,客观缓解率(ORR)方面,STRIDE方案...
曲美木单抗/替西木单抗tremelimumab (Imjudo)肝癌新药 2022年10月21日,美国FDA批准曲美木单抗tremelimumab(商品名Imjudo)与度伐利尤单抗durvalumab联合用于不能切除的肝细胞癌成年患者。 在HIMALAYA对疗效进行了评估,这是一项随机1:1:1、开放标签、多中心研究,研究对象为确诊为不可切除的肝细胞癌且之前未接受过肝细胞...
Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B) This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for...
There are no contraindications forIMFINZI®(durvalumab)or IMJUDO®(tremelimumab-actl). Severe and Fatal Immune-Mediated Adverse Reactions Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatalimmune-mediatedreactions.Immune-mediatedadv...
Imjudo (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). What Are Side Effects of Imjudo? Imjudo may cause serious side eff...
What are IMFINZI and IMJUDO? Important Safety Information What is the most important information I should know about IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl)? IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and IMJUDO can...
We aimed to assess the impact of BM and PD-L1 status on outcomes in mUC patients treated with ICIs. PATIENTS AND METHODS: This post hoc analysis of the DANUBE study included 1032 mUC patients treated with durvalumab (D), D + tremelimumab (T), or standard chemotherapy (SoC). Patients ...
曲美木单抗/替西木单抗tremelimumab (Imjudo)与度伐利尤单抗durvalumab (Imfinzi)联合用于治疗肝细胞癌(actl一种不能用手术治疗的肝癌)。曲美木单抗还与度伐利尤单抗和含铂化疗联合使用,用于治疗某种类型的非小细胞肺癌,这种肺癌已经扩散到身体的其他部位。曲美木单抗属于一类称为单克隆抗体的药物。它的工作原理是帮助你...
曲美木单抗/替西木单抗tremelimumab (Imjudo)与度伐利尤单抗durvalumab (Imfinzi)联合用于治疗肝细胞癌(actl一种不能用手术治疗的肝癌)。曲美木单抗还与度伐利尤单抗和含铂化疗联合使用,用于治疗某种类型的非小细胞肺癌,这种肺癌已经扩散到身体的其他部位。曲美木单抗属于一类称为单克隆抗体的药物。它的工作原理是帮助你...
2022年10月21日,美国FDA批准曲美木单抗tremelimumab(商品名Imjudo)与度伐利尤单抗durvalumab联合用于不能切除的肝细胞癌成年患者。 在HIMALAYA对疗效进行了评估,这是一项随机1:1:1、开放标签、多中心研究,研究对象为确诊为不可切除的肝细胞癌且之前未接受过肝细胞癌系统性治疗的患者。该批准是基于随机分配到曲美木单抗...